Roth

DOJ Case Against Live Nation Is 'Weak,' Analysts Say: 'Separating Ticketmaster... Is Unlikely To Lower Ticket Prices'

Analysts Praise Target's Q3 Results, Gross Margins, But Have Cautious Tone For Future: Retailer 'Facing The Largest Macro Headwinds'

Yelp Shares Lower As Facebook Could Get Into 'Professional Services'; Here's One Analyst's Take

Analysts Praise Target's Q3 Results, Gross Margins, But Have Cautious Tone For Future: Retailer 'Facing The Largest Macro Headwinds'

Yelp Shares Lower As Facebook Could Get Into 'Professional Services'; Here's One Analyst's Take

Digital Ally Set For Its First Profitable Quarter Since 2013, Says Roth Capital

Energous Just Lost Its CCO; What You Need To Know (And Why It Is Still A Buy)

Digital Ally Set For Its First Profitable Quarter Since 2013, Says Roth Capital

Energous Just Lost Its CCO; What You Need To Know (And Why It Is Still A Buy)

Inuvo Could Hit 65% Earnings CAGR Through 2018: How To Play It

Roth Still Loves Galmed Pharma, Keeps $20 Price Target And 'Buy' Rating

Roth Recent News

Analysts Weigh In On Amended Bluebird Bio/Celgene Deal

Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth